Description
Anti-CD80 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD80 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD80 Molecule
Background
Galiximab; 357613-77-5; IDEC-114; 16C10; CD80; CD80 molecule; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1; B7 1 antigen); CD80 molecule; T-lymphocyte activation antigen CD80; B lymphocyte activation antigen B7; B7 1; B7.1; activation B7-1 antigen;
Antibody Clone
AES-0622-ZP461
Description
Anti-CD80 FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
